[Elsevier] 50P Efficacy and safety of pemigatinib in Chinese patients with unresectable, advanced/ recurrent or metastatic intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement that failed to prior systemic therapy |
| |
post
reply
points
240